The effectiveness of sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy on total (ie, first and subsequent) CVD among patients with T2D in clinical practice remains uncertain. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.